Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer

Wang, Lihui; He, Yanli; Liu, Weijun; Bai, S. J.; Xiao, Lei; Zhang, Jie; Dhanasekaran, Saravana M.; Wang, Zhuwen; Kalyana-Sundaram, Shanker; Balbin, O. Alejandro; Shukla, Sudhanshu; Lü, Yi; Lin, Jules; Reddy, Rishindra M.; Carrott, Philip W.; Lynch, William R.; Chang, Andrew C.; Chinnaiyan, Arul M.; Beer, David G.; Zhang, Jian; Chen, Guoan

doi:10.18632/oncotarget.7203

Cited by 54 publications

(92 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 LINC00857 predicts poor patient survival and it can promote tumor progression via regulating cell cycle in lung cancer. 17 In our current study, we found that LINC00857 was greatly increased in HCC cells. Knockdown of LINC00857 was able to inhibit HCC cell proliferation, induced cell apoptosis, and blocked cell cycle progression.…”

Section: Discussionsupporting

confidence: 52%

LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial‐mesenchymal transition

Xia

Zhang

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains the fifth most frequent cancer with high mortality rate worldwide. However, the underlying molecular mechanisms of HCC progression are still barely known. Long noncoding RNAs (lncRNAs) have been recognized as significant therapeutic targets for HCC. Recently, the biological role of LINC00857 in several cancer types has been reported. Our present study was aimed to investigate the role of LINC00857 in HCC progression. We observed that LINC00857 was overexpressed in HCC cell lines (Huh7, Hep3B, HepG2, MHCC‐97H, and SNU449). Knockdown of LINC00857 significantly repressed Hep‐3B and SNU449 cell proliferation and inhibited the HCC cell colony formation. In addition, cell apoptosis was induced by the silence of LINC00857 and cell cycle progression was blocked in G1 phase. Besides these, downregulation of LINC00857 was able to restrain HCC cell migration and invasion capacity via enhancing epithelial‐mesenchymal transition (EMT) process. As displayed, E‐cadherin protein expression was increased by LINC00857 silence, while N‐cadherin protein level was repressed by LV‐shLINC00857 in HCC cells. Finally, the in vivo assays were used and the data indicated that LINC00857 could also obviously suppress the HCC tumor growth in vivo. In conclusion, our study revealed that LINC00857 might provide a novel perspective for the HCC treatment.

show abstract

Section: Discussionsupporting

confidence: 52%

LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial‐mesenchymal transition

Xia

Zhang

Liu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…AOC4P , also known as UPAT , was needed for the survival and tumorigenicity of colorectal cancer cells through regulating protein ubiquitination and degradation 41, and could also inhibit epithelial-mesenchymal transition in hepatocellular carcinoma 42. LINC00857 , which was upregulated in lung cancer, was predictive of poor patient survival and promoted tumor progression via cell cycle regulation 43. The functional and mechanistic aspects of these aberrantly expressed lncRNAs in gastric cancer need further in-depth investigation.…”

Section: Discussionmentioning

confidence: 99%

Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer

et al. 2017

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) can serve as blood-based biomarkers for cancer detection. To identify novel lncRNA biomarkers for gastric cancer (GC), we conducted, for the first time, genome-wide lncRNA screening analysis in two sets of samples: five paired preoperative and postoperative day 14 plasma samples from GC patients, and tissue samples from tumor and adjacent normal tissues. Candidate tumor-related lncRNAs were then quantitated and evaluated in three independent phases comprising 321 participants. The expression levels of lncRNAs were also measured in GC cell lines and the corresponding culture medium. Biomarker panels, lncRNA-based Index I and carcinoembryonic antigen (CEA)-based Index II, were constructed using logistic regression, and their diagnostic performance compared. Fagan's nomogram was plotted to facilitate clinical application. As a result, we identified five novel plasma lncRNAs (TINCR, CCAT2, AOC4P, BANCR and LINC00857), which, when combined in the lncRNA-based Index I, outperformed the CEA-based Index II (P < 0.001) and could distinguish GC patients from healthy controls with an area under the receiver-operating curve (AUC) of 0.91 (95% confidence interval (CI): 0.88-0.95). The lncRNA-based index decreased significantly by postoperative day 14 (P = 0.016), indicating its ability to monitor tumor dynamics. High values of the lncRNA-based index were correlated with tumor size (P = 0.036), depth of invasion (P = 0.025), lymphatic metastasis (P = 0.012) and more advanced tumor stages (P = 0.003). The lncRNA-based index was also able to discriminate GC patients from precancerous individuals and patients with gastrointestinal stromal tumor with AUC values of 0.82 (95% CI: 0.71-0.92) and 0.80 (95% CI: 0.68-0.91), respectively. Taken together, our findings demonstrate that this panel of five plasma lncRNAs could serve as a set of novel diagnostic biomarkers for GC detection.

show abstract

“…We identified 154 and 225 lncRNAs that are significantly associated with the response to Gem/Cis or platinum only treatment, respectively (Table ). Previously, LINC00857 was identified as one of the most upregulated lncRNAs in lung cancer, and high LINC00857 expression was associated with shorter overall survival of patients with lung cancer . Therefore, we decided to further focus on LINC00857 .…”

Section: Resultsmentioning

confidence: 99%

“…To further evaluate how LINC00857 contributes to platinum‐based chemotherapy response in bladder cancer, we evaluated the expression levels of LINC00857 target genes that were identified in lung cancer . In MIBC, the expression of DIAPH3 , EMR2 , MMP1 , STX12 , and UHMK1 was found to be significantly associated with response to Gem/Cis (Figure A) and other platinum‐based chemotherapy (Figure B).…”

Section: Resultsmentioning

confidence: 99%

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer

et al. 2018

View full text Add to dashboard Cite

Approximately 20% of patients with bladder cancer are diagnosed with muscle‐invasive disease (MIBC). The treatment involves radical cystectomy, but almost 50% of patients with MIBC eventually relapse and develop metastasis. The use of platinum‐based chemotherapy in the neoadjuvant setting or for metastatic patients has been shown to improve the overall survival in a subset of patients. Unfortunately, no biomarkers are available to select patients with MIBC who will benefit from chemotherapy or to monitor the efficacy of the treatment. Recently, long noncoding RNAs (lncRNAs) were shown to regulate a variety of processes involved in the development and progression of cancer, including bladder cancer. Moreover, several lncRNAs have been shown to play a role in chemotherapy resistance. Here, we analyzed lncRNA expression associated with response to platinum‐based chemotherapy in metastatic MIBC using data from the MiTranscriptome lncRNA expression database. Expression of the lncRNA,LINC00857, was found to be upregulated in tumors from patients that did not respond to platinum‐based chemotherapy. Moreover, high expression of LINC00857 is correlated with shorter recurrence‐free and overall survival of patients with MIBC. Knockdown of LINC00857 significantly decreased cell viability of bladder cancer cell lines through the induction of apoptosis. Furthermore, LINC00857 knockdown sensitized UM‐UC‐3 and T24 bladder cancer cells to cisplatin, via the negative regulation of the LMAN1 gene. Our data indicate that LINC00857 plays an important role in the regulation of response to platinum‐based chemotherapy. LINC00857 potentially could serve as a novel prognostic and predictive biomarker and might be a therapeutic target to overcome cisplatin resistance in patients with MIBC.

show abstract

Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer

Cited by 54 publications

References 52 publications

LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial‐mesenchymal transition

LINC00857 contributes to hepatocellular carcinoma malignancy via enhancing epithelial‐mesenchymal transition

Genome-Wide lncRNA Microarray Profiling Identifies Novel Circulating lncRNAs for Detection of Gastric Cancer

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer

Contact Info

Product

Resources

About